Pharma: Page 17
-
Stock via Getty Images
The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs
Although a regulatory delay for Eli Lilly’s donanemab in Alzheimer’s disease is a competitive setback, researchers have their eye on better drug development as a result.
By Michael Gibney • March 12, 2024 -
Stock via Getty Images
As colorectal deaths rise among younger people, a screening tool could help pinpoint more patients
As colorectal deaths rise among younger people, a diagnostic could help pinpoint more patients.
By Alexandra Pecci • March 12, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Scott Olson via Getty Images
COVID vaccine giants Moderna and Pfizer employ divergent tactics for the next chapter
With COVID-19 vaccine sales dying down, Pfizer and Moderna turn to growth in different ways to cement their status as mRNA leaders.
By Amy Baxter • March 11, 2024 -
Stock via Getty Images
Neurvati touts fresh, ‘synergistic’ investment model in neuroscience R&D
The Blackstone Life Sciences-backed company plans to focus on later-stage assets to help derisk development.
By Kelly Bilodeau • March 11, 2024 -
Adobe Stock / LuneVA/peopleimages.com
Sponsored by MMITWhy pharma should prioritize the patient journey: A survivor’s story
One rare disease survivor’s diagnosis experience highlights the need for pharma companies to better understand the patient journey.
By Carolyn Zele, Solution Consulting Advisor, MMIT • March 11, 2024 -
Permission granted by Tarsus Pharmaceuticals
Q&AInto the unknown: Tarsus’ CEO on its launch strategies in a new disease category
The company scored a first-in-class nod for its eye med last year, which treats a common but frequently undiagnosed condition.
By Meagan Parrish • March 8, 2024 -
Permission granted by Amylyx Pharmaceuticals
Amylyx ALS drug fails crucial study, putting company’s future in doubt
The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.
By Jacob Bell • Updated March 8, 2024 -
Mario Tama via Getty Images
J&J’s growing rare disease focus brings a potential multi-use treatment to the table
The head of J&J’s autoantibody programs believes nipocalimab is unique among potential rare disease drugs because it can harness a common thread among them.
By Michael Gibney • March 7, 2024 -
Stock via Getty Images
Big hopes for schizophrenia treatment rely on a deep pipeline of new approaches
Innovation in schizophrenia has been slow, and patients are often left with few options — but pharmas contribute to a robust lineup of candidates that could improve care.
By Kelly Bilodeau • March 6, 2024 -
Kevin Dietsch via Getty Images
Could pharma’s legal attack on the IRA succeed in killing price negotiations?
An all-out blitz across U.S. courts is bolstering pharma’s goal to overturn Medicare drug price negotiations.
By Amy Baxter • March 6, 2024 -
Permission granted by Natalie Ferguson/American Gene Technologies
ProfileHIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure
From San Francisco in the 80s to a gene therapy prospect, Dr. Marcus Conant looks back on his long fight against the virus — and if the industry is close to ending the epidemic.
By Michael Gibney • March 5, 2024 -
Anna Moneymaker via Getty Images
After ‘tragic’ bacterial outbreak, lawmakers press FDA to step up foreign inspections
Impatience to fix long-held challenges to overseas drug facility inspections is growing on Capitol Hill.
By Amy Baxter • March 1, 2024 -
Permission granted by Lindus Health
Can a top scientist and Moderna co-founder change the CRO game?
From his advisory board role at Lindus Health, Robert Langer is aiming to overcome challenges in the CRO market.
By Michael Gibney • Feb. 28, 2024 -
Stock via Getty Images
A pandemic-era staffing crunch in clinical trials is easing, but trouble spots remain
How research companies can shift strategies to attract and retain the staff that keeps trials humming along.
By Kelly Bilodeau • Feb. 28, 2024 -
Permission granted by Gianluca Pirozzi
ProfileBehind a big-name rare disease biotech, an exec draws from personal experience
The personal impact of rare disease has shaped Gianluca Pirozzi, a senior vice president at AstraZeneca’s Alexion, as a parent and drug developer.
By Alexandra Pecci • Feb. 27, 2024 -
iStock via Getty Images
How a 15-year-old Genzyme drug shortage became a legal smorgasbord of pharma’s thorniest issues
Rare disease treatments, drug shortages, a market monopoly and march-in rights all play a role in the story of newly revived litigation against Sanofi’s Genzyme.
By Alexandra Pecci • Feb. 26, 2024 -
Win McNamee via Getty Images
AbbVie CEO Richard Gonzalez leaves a divisive Humira legacy and lasting impact on pharma
Leading AbbVie to become one of the most successful pharmas in the world, Gonzalez also rubbed some critics the wrong way.
By Michael Gibney • Feb. 22, 2024 -
Stock via Getty Images
4 biotechs to watch in 2024
A splashy IPO, first-in-class treatments and upcoming approval dates are a few reasons we’ve got our eyes on these biotechs this year.
By Alexandra Pecci • Feb. 21, 2024 -
Courtesy of Kite Pharma, Inc.
Kite’s next-gen CAR-T aims include quicker production and more disease targets
While buzz builds around “off the shelf” CAR-T cell therapies, Kite is staying competitive with a shorter manufacturing turnaround and a focus on broadening applications.
By Kelly Bilodeau • Feb. 20, 2024 -
Chip Somodevilla/Getty Images via Getty Images
Biden or Trump: How deeply will 2024’s election outcome impact pharma?
The election is still months away, but campaign promises are solidifying, and signal the benefits and drawbacks of each candidate for pharma.
By Michael Gibney • Feb. 20, 2024 -
Permission granted by Avenga
Sponsored by AvengaValue and potential of IoT and AI for chronic diseases treatment
A significant growth is predicted for both AI and IoT in healthcare. By 2030, the AI market is expected to reach $187.95 billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.
By Olena Domanska, Data Science Engineering Manager at Avenga • Feb. 20, 2024 -
Courtesy of Biogen
The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround
A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.
By Michael Gibney • Feb. 15, 2024 -
stock via Getty Images
‘Hey, AI: Is Zoloft effective for me?’ Tech’s foray into predictive prescribing
Researchers are unleashing the powers of AI for precision medicine, drug development and more.
By Alexandra Pecci • Feb. 15, 2024 -
Permission granted by Pfizer
‘I wish I could see the end of the day’ — a Pfizer exec on the fight for health equity
The pharma giant’s leader of a collective devoted to health equity discusses how companies can put their money where their mouth is to reach communities in need.
By Michael Gibney • Feb. 14, 2024 -
Stock via Getty Images
3 questions hanging over the Novo-Catalent deal
As backlash builds for the recently announced matchup, critical questions remain over its impact.
By Kelly Bilodeau • Feb. 13, 2024
Previous
